Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Adenocarcinoma of the Rectum

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Adenocarcinoma of the Rectum cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
(+)-VINCRISTINE
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB

View all 31 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →